<DOC>
	<DOCNO>NCT01003717</DOCNO>
	<brief_summary>Single-center registry patient treat least one Endeavor , zotarolimus-eluting , Stent primary treatment acute coronary syndrome Washington Hospital Center , aim assess clinical success safety 30 day , 6 month annually 3 year post Endeavor Stent implantation .</brief_summary>
	<brief_title>Registry Experience Washington Hospital Center , DES - Endeavor Myocardial Infarction</brief_title>
	<detailed_description>Interventional cardiology revolutionize invention stent , initially bare-metal stent ( BMS ) recently drug-eluting stent ( DES ) .Zotarolimus-eluting stent show promising result randomize clinical trail , demonstrate reduction clinical angiographic restenosis comparison BMS , comparable clinically-driven target lesion revascularization rate comparison Sirolimus-eluting stent . While short-term 1 year registry data available outside United States , important collect `` real-world '' data regard stent usage outcome United States . In study propose follow patient receive least one EndeavorÂ® Stent primary treatment ACS 3 year post initial stent implantation .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients , male female , &gt; 18 year age Patients present acute coronary syndrome ( ACS ) , ACS define ST segment deviation &gt; 1mm elevation isoenzymes great 2x upper limit normal Patients receive least one Endeavor drugeluting stent Washington Hospital Center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>